Next Article in Journal
Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease
Next Article in Special Issue
Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications
Previous Article in Journal
Synthesis and Neuroprotective Action of Optically Pure Neoechinulin A and Its Analogs
Previous Article in Special Issue
2-Deoxystreptamine Conjugates by Truncation–Derivatization of Neomycin
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2010, 3(4), 1070-1083; doi:10.3390/ph3041070

Lessons Learned from Surveillance of Antimicrobial Susceptibilities of Pseudomonas aeruginosa at a Large Academic Medical Center

1
Clinical Pharmacy, San Francisco School of Pharmacy, University of California, 521 Parnassus Avenue UCSF Box 0622, Room C-152 San Francisco, CA 94143, USA
2
Department of Pharmaceutical Services, University of California Davis Health System, Sacramento, CA 95817, USA
3
Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, 3601 Pacific Avenue, Stockton, CA 95211, USA
This research report is dedicated to the late Jeff King, Pharm. D.
*
Author to whom correspondence should be addressed.
Received: 17 December 2009 / Revised: 22 March 2010 / Accepted: 1 April 2010 / Published: 1 April 2010
(This article belongs to the Special Issue Antibiotics)
View Full-Text   |   Download PDF [153 KB, 4 April 2010; original version 1 April 2010]   |  

Abstract

This research report assessed the differences in resistance rates and antimicrobial usage-versus-susceptibility relationships of Pseudomonas aeruginosa found in various hospital patient care areas. A simplified case control study was also performed to identify patient-specific risk factors associated with cefepime-resistant P. aeruginosa isolates. Last, we determined the consequence of combining mucoid and non-mucoid derived antimicrobial susceptibilities of P. aeruginosa into hospital antibiograms. Overall, susceptibility rates remained lower in the intensive care units (ICUs) compared to the non-ICU patient care areas, except for cefepime over the last time period. Cefepime utilization and antimicrobial-resistance rates among P. aeruginosa isolates had a significant relationship. Decreased meropenem exposure was associated with lower resistance rates relative to cefepime. Risk factors independently associated with cefepime-resistant P. aeruginosa were structural lung disease, ICU admission, recent third generation cephalosporin use, frequent hospital admission and non-urine isolates. Large and statistically significant differences were observed between non-mucoid and combined percent susceptibility data for aminoglycosides. To control antimicrobial resistance and optimize initial empiric antimicrobial therapy, antimicrobial susceptibility and utilization patterns in specific patient care areas should be monitored and risk factors for antimicrobial resistance should be assessed. Mucoid strains of P. aeruginosa should not be included into antimicrobial susceptibility data as this may underestimate activity of most antipseudomonal agents. View Full-Text
Keywords: Pseudomonas aeruginosa; antimicrobials; antibiotics; bacterial resistance; cefepime; antimicrobial stewardship; antibiogram Pseudomonas aeruginosa; antimicrobials; antibiotics; bacterial resistance; cefepime; antimicrobial stewardship; antibiogram
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Heintz, B.H.; Halilovic, J. Lessons Learned from Surveillance of Antimicrobial Susceptibilities of Pseudomonas aeruginosa at a Large Academic Medical Center. Pharmaceuticals 2010, 3, 1070-1083.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top